Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF) reported on Monday that its customer UpFront Diagnostics has commercially launched the LVOne stroke triage blood test in the UK following UKCA marking and deployment with the London Ambulance Service.

LVOne is designed to help paramedics identify large vessel occlusion strokes at the point of care using a finger-prick blood sample, with results delivered in under 10 minutes. The test measures the biomarkers D-dimer and GFAP to differentiate stroke types and support faster routing of patients for urgent treatment.

Abingdon Health acted as contract development and manufacturing organisation partner for the product, supporting feasibility, scale-up, validation, quality control and routine manufacturing of the test's dual assays. The company said the programme demonstrated its ability to support customers from product development through to commercial deployment.

The initial rollout will equip around 280 London Ambulance Service vehicles across North Central London before expanding into North West and North East London during a six-month pilot covering a population of around 6.5 million people. The programme is being led by Dr Robert Simister at University College London Hospitals in collaboration with the ambulance service and stroke centres across London.

Abingdon Health provides lateral flow assay development, manufacturing and regulatory services for the diagnostics and medical device sectors, with operations in the UK and the US.